Loading…
Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence
Purpose of Review To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recent Findings Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) w...
Saved in:
| Published in: | Current oncology reports 2020-02, Vol.22 (3), p.28-28, Article 28 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723 |
| container_end_page | 28 |
| container_issue | 3 |
| container_start_page | 28 |
| container_title | Current oncology reports |
| container_volume | 22 |
| creator | Matsuzaki, Shinya Klar, Maximilian Mikami, Mikio Shimada, Muneaki Grubbs, Brendan H. Fujiwara, Keiichi Roman, Lynda D. Matsuo, Koji |
| description | Purpose of Review
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer.
Recent Findings
Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (
N
= 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer.
Summary
Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT. |
| doi_str_mv | 10.1007/s11912-020-0888-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7759090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2353921174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723</originalsourceid><addsrcrecordid>eNp1kUtP3TAQha2qqDx_QDdVpG66STu24xcLpDaC9koXsaCsLWNPLkG5CdjJLf33dXQpLUis_JjvnJnRIeQ9hc8UQH1JlBrKSmBQgta6fHhD9qjgVSmZNG_nO-MlVwZ2yX5Kt5BB0PCO7HIGgjGo9sjy3PVuhWvsx2JoissxP4rF4ltRY9y03nVF7XqP8bhwfXGxmT_x10yON1jUU4yz8HTTBszUIdlpXJfw6PE8IFdnpz_rH-Xy4vui_rosveByLFELdc20QCEComkEVVwHzqSuQBoFwXlGgwCvIeggG-GlCZVnhlZApWL8gJxsfe-m6zUGn2eIrrN3sV27-NsOrrXPK317Y1fDxiolDBjIBp8eDeJwP2Ea7bpNHrvO9ThMyTIuKsUlFzP68QV6O0yxz-vNFDeMUlVlim4pH4eUIjZPw1Cwc1Z2m5XNEdg5K_uQNR_-3-JJ8TecDLAtkHKpX2H81_p11z99kp2c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2353921174</pqid></control><display><type>article</type><title>Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence</title><source>Springer Link</source><creator>Matsuzaki, Shinya ; Klar, Maximilian ; Mikami, Mikio ; Shimada, Muneaki ; Grubbs, Brendan H. ; Fujiwara, Keiichi ; Roman, Lynda D. ; Matsuo, Koji</creator><creatorcontrib>Matsuzaki, Shinya ; Klar, Maximilian ; Mikami, Mikio ; Shimada, Muneaki ; Grubbs, Brendan H. ; Fujiwara, Keiichi ; Roman, Lynda D. ; Matsuo, Koji</creatorcontrib><description>Purpose of Review
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer.
Recent Findings
Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (
N
= 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer.
Summary
Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-020-0888-x</identifier><identifier>PMID: 32052204</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adenocarcinoma - pathology ; Adenocarcinoma - therapy ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Carcinoma, Adenosquamous - pathology ; Carcinoma, Adenosquamous - therapy ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - therapy ; Cervical cancer ; Cervix ; Chemoradiotherapy ; Chemotherapy ; Combined Modality Therapy ; Female ; Gynecologic Cancers (NS Reed ; Humans ; Hysterectomy ; Hysterectomy - methods ; Medicine ; Medicine & Public Health ; Neoadjuvant Therapy ; Neoplasm Staging ; Oncology ; Practice Guidelines as Topic ; Prognosis ; Randomized Controlled Trials as Topic ; Section Editor ; Surgery ; Survival ; Topical Collection on Gynecologic Cancers ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - therapy</subject><ispartof>Current oncology reports, 2020-02, Vol.22 (3), p.28-28, Article 28</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723</citedby><cites>FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32052204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuzaki, Shinya</creatorcontrib><creatorcontrib>Klar, Maximilian</creatorcontrib><creatorcontrib>Mikami, Mikio</creatorcontrib><creatorcontrib>Shimada, Muneaki</creatorcontrib><creatorcontrib>Grubbs, Brendan H.</creatorcontrib><creatorcontrib>Fujiwara, Keiichi</creatorcontrib><creatorcontrib>Roman, Lynda D.</creatorcontrib><creatorcontrib>Matsuo, Koji</creatorcontrib><title>Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>Purpose of Review
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer.
Recent Findings
Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (
N
= 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer.
Summary
Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.</description><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - therapy</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Carcinoma, Adenosquamous - pathology</subject><subject>Carcinoma, Adenosquamous - therapy</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Gynecologic Cancers (NS Reed</subject><subject>Humans</subject><subject>Hysterectomy</subject><subject>Hysterectomy - methods</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Practice Guidelines as Topic</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Section Editor</subject><subject>Surgery</subject><subject>Survival</subject><subject>Topical Collection on Gynecologic Cancers</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - therapy</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kUtP3TAQha2qqDx_QDdVpG66STu24xcLpDaC9koXsaCsLWNPLkG5CdjJLf33dXQpLUis_JjvnJnRIeQ9hc8UQH1JlBrKSmBQgta6fHhD9qjgVSmZNG_nO-MlVwZ2yX5Kt5BB0PCO7HIGgjGo9sjy3PVuhWvsx2JoissxP4rF4ltRY9y03nVF7XqP8bhwfXGxmT_x10yON1jUU4yz8HTTBszUIdlpXJfw6PE8IFdnpz_rH-Xy4vui_rosveByLFELdc20QCEComkEVVwHzqSuQBoFwXlGgwCvIeggG-GlCZVnhlZApWL8gJxsfe-m6zUGn2eIrrN3sV27-NsOrrXPK317Y1fDxiolDBjIBp8eDeJwP2Ea7bpNHrvO9ThMyTIuKsUlFzP68QV6O0yxz-vNFDeMUlVlim4pH4eUIjZPw1Cwc1Z2m5XNEdg5K_uQNR_-3-JJ8TecDLAtkHKpX2H81_p11z99kp2c</recordid><startdate>20200212</startdate><enddate>20200212</enddate><creator>Matsuzaki, Shinya</creator><creator>Klar, Maximilian</creator><creator>Mikami, Mikio</creator><creator>Shimada, Muneaki</creator><creator>Grubbs, Brendan H.</creator><creator>Fujiwara, Keiichi</creator><creator>Roman, Lynda D.</creator><creator>Matsuo, Koji</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200212</creationdate><title>Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence</title><author>Matsuzaki, Shinya ; Klar, Maximilian ; Mikami, Mikio ; Shimada, Muneaki ; Grubbs, Brendan H. ; Fujiwara, Keiichi ; Roman, Lynda D. ; Matsuo, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - therapy</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Carcinoma, Adenosquamous - pathology</topic><topic>Carcinoma, Adenosquamous - therapy</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Gynecologic Cancers (NS Reed</topic><topic>Humans</topic><topic>Hysterectomy</topic><topic>Hysterectomy - methods</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Practice Guidelines as Topic</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Section Editor</topic><topic>Surgery</topic><topic>Survival</topic><topic>Topical Collection on Gynecologic Cancers</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsuzaki, Shinya</creatorcontrib><creatorcontrib>Klar, Maximilian</creatorcontrib><creatorcontrib>Mikami, Mikio</creatorcontrib><creatorcontrib>Shimada, Muneaki</creatorcontrib><creatorcontrib>Grubbs, Brendan H.</creatorcontrib><creatorcontrib>Fujiwara, Keiichi</creatorcontrib><creatorcontrib>Roman, Lynda D.</creatorcontrib><creatorcontrib>Matsuo, Koji</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuzaki, Shinya</au><au>Klar, Maximilian</au><au>Mikami, Mikio</au><au>Shimada, Muneaki</au><au>Grubbs, Brendan H.</au><au>Fujiwara, Keiichi</au><au>Roman, Lynda D.</au><au>Matsuo, Koji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2020-02-12</date><risdate>2020</risdate><volume>22</volume><issue>3</issue><spage>28</spage><epage>28</epage><pages>28-28</pages><artnum>28</artnum><issn>1523-3790</issn><eissn>1534-6269</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-Review-3</notes><notes>content type line 23</notes><notes>ObjectType-Undefined-4</notes><abstract>Purpose of Review
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer.
Recent Findings
Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (
N
= 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer.
Summary
Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32052204</pmid><doi>10.1007/s11912-020-0888-x</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2020-02, Vol.22 (3), p.28-28, Article 28 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7759090 |
| source | Springer Link |
| subjects | Adenocarcinoma - pathology Adenocarcinoma - therapy Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Adenosquamous - pathology Carcinoma, Adenosquamous - therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - therapy Cervical cancer Cervix Chemoradiotherapy Chemotherapy Combined Modality Therapy Female Gynecologic Cancers (NS Reed Humans Hysterectomy Hysterectomy - methods Medicine Medicine & Public Health Neoadjuvant Therapy Neoplasm Staging Oncology Practice Guidelines as Topic Prognosis Randomized Controlled Trials as Topic Section Editor Surgery Survival Topical Collection on Gynecologic Cancers Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - therapy |
| title | Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T08%3A39%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Stage%20IIB%20Cervical%20Cancer:%20an%20Overview%20of%20the%20Current%20Evidence&rft.jtitle=Current%20oncology%20reports&rft.au=Matsuzaki,%20Shinya&rft.date=2020-02-12&rft.volume=22&rft.issue=3&rft.spage=28&rft.epage=28&rft.pages=28-28&rft.artnum=28&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-020-0888-x&rft_dat=%3Cproquest_pubme%3E2353921174%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c536t-e857b285e55dee9f51738d3268406970dac21d50c80d8d6f5c69d4c2914016723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2353921174&rft_id=info:pmid/32052204&rfr_iscdi=true |